c Core One Labs (CLABF) | Emerging Markets Consulting, Llc.

Core One Labs logoSymbol: OTC:CLABF

  • Core One Labs - Lab Outstanding Shares: 108,999,774
  • Float: Not Available


Core One Labs - Bob Hancock videoCore One Labs is a biotech company focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Under the guidance of world-leading microbiologist Executive Chairman Dr. Bob Hancock, Core One is developing new ways for producing psilocybin at a fraction of the price of the current market. Estimated market price is $7,000 to $10,000 USD per gram for synthetic psilocybin used in clinical trials. By using Core One's biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively for $10s to $100s of dollars.

Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Survey Findings

  • An online survey of 430 investors who use online broker platforms found that half of respondents between 25 and 34 years old plan to spend 50% of their stimulus payments on stocks.
  • Meanwhile, 18- to 24-year-old retail investors involved in the survey planned to use 40% of any stimulus checks on stocks.
  • And 35- to 54-year-old retail investors surveyed planned to use 37% of their checks on stock market investment.

View Survey Findings

Subscribe to Receive Client Updates Delivered Straight To Your Inbox

Recent News

Emerging Markets Report

View/Print the Core One Labs Fact Sheet

Must Read OTC Markets/SEC policy on stock promotion and investor protection


EMC has a contract to be paid 300,000 dollars by Core One Labs, Inc. | Please read our full disclaimer